Rina Hui
Institut Gustave Roussy
4 papers in the Anchorcite directory, published between 2015 and 2018, cited 28,039 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 4 papers
- Lung Cancer Treatments and Mutations · 4 papers
- Lung Cancer Diagnosis and Treatment · 3 papers
- Lung Cancer Research Studies · 1 paper
Frequent co-authors
- Delvys Rodríguez‐Abreu · 2 papers
- Nir Peled · 2 papers
- Gregory M. Lubiniecki · 2 papers
- Reshma A. Rangwala · 2 papers
- Leena Gandhi · 2 papers
- Enriqueta Felip · 2 papers
- Edward B. Garon · 2 papers
- Jhanelle E. Gray · 2 papers
Papers
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung CancerNew England Journal of Medicine · 2016 · 10,276 citations
BACKGROUND: Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in advanced non-small-cell lung cancer (NSCLC), with increased activity in tumors that express programmed death ligand 1 (PD-L1). METHODS: In this open-label, phase 3…
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine · 2018 · 6,754 citations
BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced cytotoxic chemotherapy as the…
- Pembrolizumab for the Treatment of Non–Small-Cell Lung CancerNew England Journal of Medicine · 2015 · 6,294 citations
BACKGROUND: We assessed the efficacy and safety of programmed cell death 1 (PD-1) inhibition with pembrolizumab in patients with advanced non-small-cell lung cancer enrolled in a phase 1 study. We also sought to define and validate an expression level of…
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung CancerNew England Journal of Medicine · 2017 · 4,715 citations
BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in…
Metadata from OpenAlex (CC0).